ATE140387T1 - Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung von omeprazol sind - Google Patents

Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung von omeprazol sind

Info

Publication number
ATE140387T1
ATE140387T1 AT92107179T AT92107179T ATE140387T1 AT E140387 T1 ATE140387 T1 AT E140387T1 AT 92107179 T AT92107179 T AT 92107179T AT 92107179 T AT92107179 T AT 92107179T AT E140387 T1 ATE140387 T1 AT E140387T1
Authority
AT
Austria
Prior art keywords
discoloring
omeprazole
layers
core material
pharmaceutical formulations
Prior art date
Application number
AT92107179T
Other languages
English (en)
Inventor
Kurt Loevgren
Ake Pilbrant
Mitsuru Yasumura
Satoshi Morigaki
Minoru Oda
Naohiro Ohishi
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26290693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE140387(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Application granted granted Critical
Publication of ATE140387T1 publication Critical patent/ATE140387T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92107179T 1986-04-30 1987-04-16 Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung von omeprazol sind ATE140387T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB08610572A GB2189698A (en) 1986-04-30 1986-04-30 Coated omeprazole tablets
SG154294A SG154294G (en) 1986-04-30 1994-10-21 New pharmaceutical preparation for oral use

Publications (1)

Publication Number Publication Date
ATE140387T1 true ATE140387T1 (de) 1996-08-15

Family

ID=26290693

Family Applications (3)

Application Number Title Priority Date Filing Date
AT92107179T ATE140387T1 (de) 1986-04-30 1987-04-16 Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung von omeprazol sind
AT87850127T ATE84215T1 (de) 1986-04-30 1987-04-16 Arzneizubereitung zur oralen anwendung.
AT93201611T ATE184482T1 (de) 1986-04-30 1987-04-16 Vehikel für die orale verabreichung säurelabiler pharmaka

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT87850127T ATE84215T1 (de) 1986-04-30 1987-04-16 Arzneizubereitung zur oralen anwendung.
AT93201611T ATE184482T1 (de) 1986-04-30 1987-04-16 Vehikel für die orale verabreichung säurelabiler pharmaka

Country Status (35)

Country Link
US (1) US4786505A (de)
EP (3) EP0567201B1 (de)
JP (2) JPS62258320A (de)
KR (1) KR910004579B1 (de)
CN (1) CN1020852C (de)
AR (1) AR240250A1 (de)
AT (3) ATE140387T1 (de)
CA (1) CA1292693C (de)
CY (1) CY1810A (de)
DD (1) DD273197A5 (de)
DE (3) DE3751860T2 (de)
DK (1) DK169988B1 (de)
DZ (1) DZ1077A1 (de)
ES (3) ES2006457T3 (de)
FI (1) FI90393C (de)
GB (1) GB2189698A (de)
GR (4) GR890300058T1 (de)
HK (2) HK135294A (de)
HR (1) HRP920854B1 (de)
HU (1) HU196708B (de)
IE (1) IE61416B1 (de)
IL (1) IL82911A (de)
IS (1) IS1917B (de)
LT (1) LT3699B (de)
LV (2) LV10357B (de)
NO (1) NO174239C (de)
NZ (1) NZ220096A (de)
PH (1) PH25701A (de)
PL (1) PL151631B1 (de)
PT (1) PT84785B (de)
RU (2) RU1820837C (de)
SG (1) SG154294G (de)
SI (1) SI8710681A8 (de)
YU (1) YU46192B (de)
ZA (1) ZA872378B (de)

Families Citing this family (366)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749864B2 (en) * 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
JPH0737383B2 (ja) * 1988-07-11 1995-04-26 エーザイ株式会社 胃酸分泌抑制剤含有固型製剤
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
EP0425699B1 (de) * 1989-05-11 1994-08-17 Chugai Seiyaku Kabushiki Kaisha Mundzubereitung zur verabreichung an bestimmter stelle des darmes
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DE69127275T2 (de) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
DE69231313T2 (de) * 1991-11-22 2001-03-15 Procter & Gamble Pharmaceuticals, Inc. Risedronat enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
GB9223702D0 (en) 1992-11-12 1992-12-23 Lucas Ind Plc Improvements in hydraulic braking systems for vehicles
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
TW397686B (en) * 1993-08-11 2000-07-11 Takeda Chemical Industries Ltd Antacid compositions and pharmaceutical compositions
TW280770B (de) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
US5714505A (en) * 1994-01-05 1998-02-03 Astra Aktiebolag Method for treatment of psoriasis, by omeprazole or related compounds
EP0746310B1 (de) * 1994-02-23 1998-11-18 BM Research A/S Zusammensetzung mit gesteuerter freisetzung
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
WO1996001622A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag New oral pharmaceutical formulation containing magnesium salt of omeprazole
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
AU694818B2 (en) * 1994-11-21 1998-07-30 Shell Internationale Research Maatschappij B.V. Bitumen compositions
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
CN1183715A (zh) * 1995-05-09 1998-06-03 科洛康有限公司 适合药物基质静电包衣的粉末包衣物质
GB2316342B (en) * 1995-05-09 2000-01-12 Colorcon Ltd Electrostatic coating
US7008668B2 (en) 1995-05-09 2006-03-07 Phoqus Pharmaceuticals Limited Powder coating composition for electrostatic coating of pharmaceutical substrates
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
DE69631981T2 (de) * 1995-09-21 2005-04-14 Pharma Pass Ii Llc, Irvine Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
ZA979937B (en) * 1996-11-06 1999-05-18 Sharmatek Inc Delayed delivery system for acid-sensitive drugs
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
GB9623634D0 (en) * 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
WO1998023272A1 (en) * 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions and methods for the treatment of gastrointestinal disorders
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
AU7375598A (en) * 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE19752843C2 (de) * 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
US6328993B1 (en) * 1997-12-08 2001-12-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for an acid liable active proton pump inhibitor
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
ES2559766T3 (es) 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
CA2340054C (en) * 1998-08-12 2005-10-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100314351B1 (ko) * 1998-10-01 2002-03-21 민경윤 벤즈이미다졸유도체의장용성제제및그제조방법
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
CN100503598C (zh) * 1998-11-18 2009-06-24 阿斯特拉曾尼卡有限公司 改进的化学方法和药物制剂
RU2144823C1 (ru) * 1998-11-20 2000-01-27 Научно-исследовательский институт фармакологии Томского научного центра РАМН Лекарственное средство, обладающее слабительным действием
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
TWI268779B (en) 1999-10-20 2006-12-21 Eisai Co Ltd Method for stabilizing benzimidazole-based compounds
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
GB0002305D0 (en) 2000-02-01 2000-03-22 Phoqus Limited Power material for electrostatic application
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
US20030190360A1 (en) * 2001-03-13 2003-10-09 Baichwal Anand R. Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
WO2002096394A2 (en) * 2001-05-30 2002-12-05 Euro-Celtique S.A. Pharmaceutical composition containing stool softener such as polaxamer and enteric coated particles of bisacodyl
MXPA03011017A (es) * 2001-06-01 2005-04-29 Pozen Inc Composiciones farmaceuticas para la entrega coordinada de nsaids.
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
EP1429745A2 (de) 2001-09-28 2004-06-23 McNEIL-PPC, INC. Zusammengesetzte darreichungsformen mit einem eingelagerten anteil
ES2392960T3 (es) * 2001-10-17 2012-12-17 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
DE60314105T2 (de) * 2002-03-05 2008-01-24 Astrazeneca Ab Alkylammoniumsalze von omeprazol und esomeprazol
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
AU2003209534A1 (en) * 2002-03-08 2003-09-22 Bakulesh Mafatlal Khamar The method of treating tuberculosis
US20030180358A1 (en) * 2002-03-25 2003-09-25 Stumberger Walter William System and method for affecting the pH state of the contents of the distal bowel in mammals
CA2477841A1 (en) * 2002-03-28 2003-10-09 Astrazeneca Ab Method of use
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
PL208130B1 (pl) * 2002-08-02 2011-03-31 Ratiopharm Gmbh Preparat farmaceutyczny zawierający związek benzoimidazolu w mieszaninie z celulozą mikrokrystaliczną oraz sposób jego otrzymywania
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP2596792A1 (de) 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stabile, feste Präparate
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
CA2511540A1 (en) * 2002-12-23 2004-07-22 Celltech Americas, Inc. Acid labile drug compositions
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
WO2004080439A1 (ja) 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited 高濃度に活性成分を球形核に付着させた医薬組成物
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
WO2004093875A1 (en) * 2003-04-22 2004-11-04 Dr. Reddy's Laboratories Limited Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
GB2420297B (en) * 2003-06-18 2006-11-15 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
MXPA06000577A (es) * 2003-07-17 2006-07-03 Reddy S Lab Ltd Composiciones farmaceuticas que tienen un recubrimiento hinchable.
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
EP1660052A2 (de) * 2003-09-03 2006-05-31 Agi Therapeutics Limited Protonenpumpenhemmer-formulierungen und verfahren zur herstellung und verwendung dieser formulierungen
MXPA06003101A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
EP1670442A4 (de) * 2003-09-19 2011-09-14 Penwest Pharmaceuticals Co Dosierformen mit verzögerter freisetzung
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
EP1667681A4 (de) * 2003-10-03 2009-09-30 Astron Res Pvt Ltd Neues transmukosales abgabesystem
WO2005040816A1 (en) * 2003-10-24 2005-05-06 Immunaid Pty Ltd Method of therapy
EP1677770A2 (de) * 2003-10-31 2006-07-12 Dexcel Ltd. Stabile lansoprazol-formulierung
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
GB0330171D0 (en) * 2003-12-30 2004-02-04 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
WO2005065726A1 (en) * 2003-12-30 2005-07-21 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
WO2005084649A1 (ja) * 2004-03-04 2005-09-15 Takeda Pharmaceutical Company Limited 安定なカプセル剤
PT1729797E (pt) * 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
GB0407312D0 (en) * 2004-03-31 2004-05-05 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06013585A (es) * 2004-05-25 2009-07-22 Santarus Inc Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para hacer y utilizar las mismas.
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
JP2008502740A (ja) * 2004-06-15 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド ベンズイミダゾール化合物の安定医薬製剤
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
TWI361078B (en) * 2004-09-20 2012-04-01 Ltb4 Sweden Ab Stabilized leukotriene b4 (ltb4) agent pharmaceutical formulation
EP1830823A2 (de) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stabile orale benzimidazol-zusammensetzungen und herstellungsverfahren
US20090208575A1 (en) * 2005-01-03 2009-08-20 Lupin Limited Pharmaceutical Composition Of Acid Labile Substances
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
WO2006087613A2 (en) * 2005-02-02 2006-08-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
JP5140586B2 (ja) 2005-07-29 2013-02-06 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 滅菌パンクレアチン粉末の製法
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
DK1931316T4 (en) * 2005-08-15 2017-05-15 Abbott Laboratories Gmbh Controlled-release pharmaceutical compositions for use in acid-labile drugs
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
DE602006012346D1 (de) * 2005-08-15 2010-04-01 Solvay Pharm Gmbh Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
WO2007041790A1 (en) * 2005-10-14 2007-04-19 Jon Pty Limited Salts of proton pump inhibitors and process for preparing same
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
EP1785135A1 (de) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. Neue Lanzoprazol enthaltende stabilisierte galenische Formulierungen und ihre Herstellung
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
NZ568471A (en) 2005-12-05 2010-09-30 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1967211A4 (de) 2005-12-28 2009-12-30 Takeda Pharmaceutical Verfahren zur herstellung eines sich in der mundhöhle zersetzenden feststoffpräparats
CA2634637A1 (en) * 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited Controlled release solid preparation
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
US20070190145A1 (en) * 2006-01-27 2007-08-16 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
NZ569984A (en) 2006-01-27 2011-06-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
WO2007090113A2 (en) 2006-02-01 2007-08-09 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
ES2699444T3 (es) * 2006-04-04 2019-02-11 Kg Acquisition Llc Formas de dosificación oral que incluyen un agente antiplaquetario y un inhibidor ácido
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
AR056062A1 (es) 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
EP2124556B1 (de) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
AU2007311493B2 (en) * 2006-10-17 2013-01-31 Ranbaxy Laboratories Limited Multiple unit tablet compositions of benzimidazole compounds
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20110174855A1 (en) * 2006-11-29 2011-07-21 Yakima Products, Inc. Vehicle top carriers
EP2478895A3 (de) 2006-12-22 2012-12-19 Ironwood Pharmaceuticals, Inc. Zusammensetzungen zur Behandlung von Speiseröhrenerkrankungen
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
CN101686943B (zh) * 2007-02-20 2014-03-26 阿普塔利斯制药有限公司 稳定的消化酶组合物
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
KR101443943B1 (ko) * 2007-05-07 2014-10-07 에보니크 룀 게엠베하 가속된 약물 방출을 갖는 장용 코팅을 포함하는 고체 투여 형태
US20090023771A1 (en) * 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
WO2009049160A1 (en) 2007-10-12 2009-04-16 Takeda Pharmaceuticals North America Methods of treating gastrointestinal disorders independent of the intake of food
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
EP2303238A1 (de) * 2008-06-30 2011-04-06 Merck Sharp & Dohme Corp. Feste dosierformen von telcagepant-kalium
AU2008359725A1 (en) * 2008-07-24 2010-01-28 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
US20110150945A1 (en) * 2008-08-11 2011-06-23 Mepha Gmbh Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
DE102008045339A1 (de) 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmazeutisches Pellet
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
KR20110124780A (ko) 2009-02-24 2011-11-17 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
US9122778B2 (en) 2009-05-27 2015-09-01 Biotempus Limited Methods of treating diseases
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP3311667A1 (de) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
JP2011037787A (ja) * 2009-08-13 2011-02-24 Kyorin Pharmaceutical Co Ltd 塩基性薬物のｐＨに依存しない安定放出組成物
WO2011025673A1 (en) * 2009-08-26 2011-03-03 Aptapharma, Inc. Multilayer minitablets
EP2319504A1 (de) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Feste pharmazeutische Dosierform
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2011138797A2 (en) 2010-05-04 2011-11-10 Cadila Healthcare Limited Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN103221036A (zh) 2010-10-01 2013-07-24 阿普塔利斯制药有限公司 肠溶包衣的低强度胰脂肪酶制剂
DE102010052847A1 (de) 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
PL2672981T3 (pl) 2011-02-11 2018-09-28 Zx Pharma, Llc Wielocząstkowe preparaty l-mentolu i powiązane sposoby
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
KR101953413B1 (ko) 2011-08-08 2019-02-28 앨러간 파마슈티컬스 인터내셔널 리미티드 소화효소들을 함유하는 고형 조성물들의 용해 시험 방법
GB201117480D0 (en) * 2011-10-10 2011-11-23 Palikaras George Filter
EP2601947A1 (de) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Kombinationspräparat mit fester Dosierung zur Behandlung von Erkrankungen einhergehend mit Helicobacter pylori
EP2797600A4 (de) 2011-12-28 2015-09-16 Pozen Inc Verbesserte zusammensetzungen und verfahren zur abgabe von omeprazol und acetylsalicylsäure
CA2867891C (en) 2012-03-19 2021-09-14 Buck Institute For Research On Aging App specific bace inhibitors (asbis) and uses thereof
JP2015524477A (ja) 2012-08-07 2015-08-24 バック・インスティテュート・フォー・リサーチ・オン・エイジング 神経機能を改善するための多成分製剤
CN102940611B (zh) * 2012-11-26 2017-02-22 康普药业股份有限公司 一种含有埃索美拉唑镁的肠溶片剂
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
CN105338958A (zh) 2013-01-15 2016-02-17 铁木医药有限公司 胆汁酸螯合剂的胃内滞留缓释口服剂型
US10202355B2 (en) 2013-02-12 2019-02-12 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
WO2014136494A1 (ja) * 2013-03-08 2014-09-12 富士フイルム株式会社 腸溶性細粒及び医薬組成物
KR101787225B1 (ko) 2013-04-23 2017-10-18 제트엑스 파마 엘엘씨 단백질성 서브코트를 갖는 장용 코팅된 다중 미립자 조성물
ES2784227T3 (es) 2013-08-09 2020-09-23 Allergan Pharmaceuticals Int Ltd Composición de enzimas digestivos adecuada para la administración entérica
EP3082777A4 (de) * 2013-12-20 2017-06-21 9286-3620 Québec Inc. Proteinbasierte enterische beschichtung für orale darreichungsformen
CN104337788B (zh) * 2013-12-30 2016-05-11 成都迪康药业有限公司 埃索美拉唑钠肠溶制剂及其制备方法
CN104337789B (zh) * 2013-12-30 2016-05-11 成都迪康药业有限公司 雷贝拉唑钠肠溶制剂及其制备方法
CN104586772A (zh) * 2013-12-30 2015-05-06 四川迪康科技药业股份有限公司 质子泵抑制剂肠溶制剂及其包衣系统和制备方法
KR101658275B1 (ko) 2014-01-20 2016-09-20 대원제약주식회사 에스오메프라졸 함유 소형 의약정제
WO2015153841A1 (en) 2014-04-04 2015-10-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
EP3157568A1 (de) 2014-06-19 2017-04-26 Aptalis Pharma Limited Verfahren zur entfernung von viralen verunreinigungen aus pankreatischen extrakten
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
US12472149B2 (en) 2015-07-17 2025-11-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
PL3324948T3 (pl) * 2015-07-17 2023-06-26 BE Pharbel Manufacturing Wielowarstwowe mikrocząstki uwalniające związek farmaceutycznie aktywny w płynnej postaci dawkowania
BE1024339B1 (fr) * 2016-07-01 2018-01-29 Be Pharbel Mfg Sa Microparticules multicouches libérant un composé pharmaceutiquement actif dans une forme pharmaceutique liquide
EP3117824A1 (de) * 2015-07-17 2017-01-18 BE Pharbel Manufacturing Mehrschichtige mikropartikel zur freigabe einer pharmazeutisch aktiven verbindung in einer flüssigen verabreichungsform
CN117562898A (zh) * 2015-11-27 2024-02-20 西姆莱斯有限公司 具有奥美拉唑或泮托拉唑的口服配制品
EP4218739A3 (de) 2016-01-08 2023-08-09 The Regents of The University of California Mesoporöse siliciumdioxidnanopartikel mit lipiddoppelschichtbeschichtung zur frachtlieferung
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
IL262957B2 (en) 2016-05-12 2024-04-01 Buck Inst Res Aging 6-Fluorotropistrone and a pharmaceutical formulation comprising it for the relief of amyloid-related diseases
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (de) 2016-09-07 2018-03-14 Sandoz Ag Omeprazolformulierungen
EP3600320A4 (de) * 2017-03-31 2020-12-16 Acura Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur selbstregulierten freisetzung von pharmazeutischen wirkstoffen
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
US11992495B2 (en) 2017-06-23 2024-05-28 The Regents Of The University Of California Enhancing GABA's ability to modulate immune responses
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
US12383499B2 (en) 2018-01-01 2025-08-12 The Regents Of The University Of California Scale up synthesis of silicasome nanocarriers
KR102080023B1 (ko) * 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
RU2694527C1 (ru) 2018-02-06 2019-07-16 Шмуэль Борис Левит Комбинация для регенеративной терапии больных сахарным диабетом 1 типа
EP3610860A1 (de) * 2018-08-15 2020-02-19 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Zusammensetzung aus kohlendioxidabsorptionsmittel oder -adsorptionsmittel, wobei die besagte zusammensetzung eine aus silikonkautschuk und cellulose ausgewählte polymerbeschichtung enthält
US12251375B2 (en) 2018-08-23 2025-03-18 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
KR102643707B1 (ko) 2019-01-22 2024-03-04 에오비안 파마슈티컬스, 인크. Mtorc 조절제 및 이의 용도
EP3986163A2 (de) 2019-06-19 2022-04-27 Solarea Bio, Inc. Mikrobielle zusammensetzungen und verfahren zur herstellung von aufgewerteten probiotischen zusammenstellungen
TW202126301A (zh) * 2019-10-04 2021-07-16 愛爾蘭商席歐拉斯製藥有限公司 小兒懸浮調配物
JP7624444B2 (ja) 2019-12-11 2025-01-30 エボニック オペレーションズ ゲーエムベーハー 病気の治療又は予防において使用するための剤形
MX2022007160A (es) * 2019-12-11 2022-07-11 Evonik Operations Gmbh Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad.
US20230000780A1 (en) * 2019-12-11 2023-01-05 Evonik Operations Gmbh Dosage form comprising an alkaline agent and an enteric coating layer
CN114569579B (zh) * 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
CN114569580B (zh) * 2020-12-02 2024-03-01 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
ES2924573B2 (es) * 2021-03-18 2024-04-24 Aora Health S L Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal
CN112919975B (zh) * 2021-04-01 2022-02-11 山东爱福地生物股份有限公司 一种智能调控土壤酸碱度的有机肥的生产工艺
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
CA3245419A1 (en) 2022-03-04 2023-09-07 Revagenix, Inc. Broad-spectrum aminoglycosides and their uses
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
GB760403A (en) * 1952-10-16 1956-10-31 Abbott Lab Improvements in or relating to enteric coatings
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
DE1617615A1 (de) * 1966-05-03 1971-03-25 Merck Patent Gmbh Verfahren zur Herstellung von oral vertraeglichen festen Arzneimittelzubereitungen mit Resorptionsverzoegerung
GB1190387A (en) * 1966-05-24 1970-05-06 Green Cross Corp Enteric Coated Medicaments
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
ZA743391B (en) * 1974-05-28 1975-08-27 A Warren Therapeutic products
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4382091A (en) * 1981-04-30 1983-05-03 Syntex (U.S.A.) Inc. Stabilization of 1-substituted imidazole derivatives in talc
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
JPS58135806A (ja) * 1982-02-08 1983-08-12 Nippon Kayaku Co Ltd 多層コ−チング製剤
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
DE3233764C2 (de) * 1982-09-11 1987-05-07 R.P. Scherer GmbH, 6930 Eberbach Verfahren zur Herstellung oraler Dosierungseinheiten
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS6019715A (ja) * 1983-07-12 1985-01-31 Nisshin Flour Milling Co Ltd 安定なイソカルボスチリル製剤
WO1985003436A1 (en) * 1984-02-10 1985-08-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
US4685919A (en) * 1985-03-14 1987-08-11 Ngk Spark Plug Co., Ltd. Artificial joint
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) * 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物

Also Published As

Publication number Publication date
DE247983T1 (de) 1990-09-27
NO174239B (no) 1993-12-27
DD273197A5 (de) 1989-11-08
NO871790D0 (no) 1987-04-29
KR870009717A (ko) 1987-11-30
JPS62258320A (ja) 1987-11-10
CN1020852C (zh) 1993-05-26
DK215887D0 (da) 1987-04-28
EP0247983A2 (de) 1987-12-02
SG154294G (en) 1995-03-17
ES2091971T3 (es) 1996-11-16
NZ220096A (en) 1990-04-26
LV5760A4 (lv) 1996-12-20
LV5760B4 (lv) 1997-06-20
ATE184482T1 (de) 1999-10-15
EP0496437B1 (de) 1996-07-17
GB2189698A (en) 1987-11-04
EP0567201A3 (de) 1995-06-07
AU601974B2 (en) 1990-09-27
EP0496437A3 (en) 1992-09-02
CA1292693C (en) 1991-12-03
HRP920854B1 (en) 1998-12-31
PL151631B1 (en) 1990-09-28
GR3020734T3 (en) 1996-11-30
LTIP1683A (en) 1995-07-25
KR910004579B1 (ko) 1991-07-06
AR240250A1 (es) 1990-03-30
DE3751860D1 (de) 1996-08-22
EP0567201B1 (de) 1999-09-15
ZA872378B (en) 1987-12-30
DK169988B1 (da) 1995-04-24
EP0247983A3 (en) 1988-10-19
HK135294A (en) 1994-12-09
DE3783394T2 (de) 1993-05-06
LT3699B (en) 1996-02-26
GR890300058T1 (en) 1989-06-22
LV10357A (lv) 1995-02-20
FI871913A0 (fi) 1987-04-29
RU2095054C1 (ru) 1997-11-10
JPH05294831A (ja) 1993-11-09
IL82911A (en) 1991-06-30
GR3032101T3 (en) 2000-03-31
ATE84215T1 (de) 1993-01-15
NO174239C (no) 1994-04-06
DZ1077A1 (fr) 2004-09-13
HUT43954A (en) 1988-01-28
EP0567201A2 (de) 1993-10-27
YU46192B (sh) 1993-05-28
CY1810A (en) 1995-10-20
HK52897A (en) 1997-05-02
ES2006457T3 (es) 1994-01-01
DE3751860T2 (de) 1996-11-21
YU68187A (en) 1988-12-31
JP2740993B2 (ja) 1998-04-15
US4786505A (en) 1988-11-22
PT84785A (en) 1987-05-01
HU196708B (en) 1989-01-30
IE61416B1 (en) 1994-11-02
RU1820837C (ru) 1993-06-07
CN87103284A (zh) 1987-11-11
PT84785B (pt) 1989-12-29
FI90393C (sv) 1994-02-10
EP0496437A2 (de) 1992-07-29
NO871790L (no) 1987-11-02
IE871107L (en) 1987-10-30
DK215887A (da) 1987-10-31
FI871913L (fi) 1987-10-31
GR3007434T3 (de) 1993-07-30
PH25701A (en) 1991-09-18
LV10357B (en) 1996-04-20
ES2006457A4 (es) 1989-05-01
ES2135443T3 (es) 1999-11-01
IS1917B (is) 2004-03-15
PL265416A1 (en) 1988-07-21
GB8610572D0 (en) 1986-06-04
EP0247983B1 (de) 1993-01-07
HRP920854A2 (en) 1994-10-31
SI8710681A8 (en) 1996-10-31
IS3221A7 (is) 1987-10-31
JP5069807B2 (de) 1993-10-01
AU7191287A (en) 1987-11-05
DE3783394D1 (de) 1993-02-18
FI90393B (fi) 1993-10-29

Similar Documents

Publication Publication Date Title
ATE140387T1 (de) Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung von omeprazol sind
ATE139692T1 (de) Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung säurelabiler verbindungen sind
PT85616A (de) Aryloxycarbonsaurederivate ihre herstellung und verwendung
DE3751845D1 (de) Stabilisiertes Arzneimittel und dessen Herstellung
DE3673047D1 (de) (imidazolyl-4)-piperidine, ihre herstellung und anwendung als heilmittel.
DE3882848D1 (de) Kosmetikbasiszubereitung mit arzneimitteleigenschaften.
DE3789761D1 (de) Reibungsmaterialien und Herstellung derselben.
DE10199018I1 (de) Thiazolidindion-Derivate deren Herstellung und Anwendung
FI891591A7 (fi) Ihonhoitokoostumus ja menetelmä sen valmistamiseksi
DE3650339D1 (de) Herstellung von Urandioxid-Material.
DE69307733D1 (de) Calix-[4]-arene-bis-kronen, ihre herstellung und ihre anwendung zur selektiven extrahierung von cäsium und aktiniden
DE3585883D1 (de) Gesintertes zirkon und dessen herstellung.
DE3780415D1 (de) Polyphasenstruktur und deren herstellung.
DK668487A (da) Kosmetisk praeparat
PT81531A (de) Verfahren zur herstellung von isosilybinfreiem silibinin und araneimittel enthaltend silibinina
IT1172093B (it) Dibenzazepine loro preparazione e loro impiego come medicamenti
DE3883108D1 (de) Thermographiematerial und dessen herstellung.
DE3688212D1 (de) Streckblasgeformter behaelter aus polyarylaenthioaether und herstellung davon.
ATA56194A (de) Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln
DE3581210D1 (de) Immunotoxin und herstellung.
DE3885384D1 (de) Organosilikonverbindungen, deren Herstellung und Anwendung.
DE3789352D1 (de) Neue biphenylabkömmlinge, deren herstellung und verwendung.
IT1215392B (it) Formulazioni cosmetiche
PT77380B (de) Piperidinderivate ihre herstellung und verwendung
DE69128176D1 (de) Herstellung von Fluorphenolen, Fluorhalophenolen, N-Azylfluoranilinen und N-Azylfluorhaloanilinen

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time